Literature DB >> 32711187

The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.

Emmanuel Somm1, Sophie A Montandon2, Ursula Loizides-Mangold3, Nadia Gaïa4, Vladimir Lazarevic4, Claudio De Vito5, Elodie Perroud2, Marie-Luce Bochaton-Piallat6, Charna Dibner3, Jacques Schrenzel7, François R Jornayvaz8.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disorder related to type 2 diabetes (T2D). The disease can evolve toward nonalcoholic steatohepatitis (NASH), a state of hepatic inflammation and fibrosis. There is presently no drug that effectively improves and/or prevents NAFLD/NASH/fibrosis. GLP-1 receptor agonists (GLP-1Ra) are effective in treating T2D. As with the endogenous gut incretins, GLP-1Ra potentiate glucose-induced insulin secretion. In addition, GLP-1Ra limit food intake and weight gain, additional beneficial properties in the context of obesity/insulin-resistance. Nevertheless, these pleiotropic effects of GLP-1Ra complicate the elucidation of their direct action on the liver. In the present study, we used the classical methionine-choline deficient (MCD) dietary model to investigate the potential direct hepatic actions of the GLP-1Ra liraglutide. A 4-week infusion of liraglutide (570 µg/kg/day) did not impact body weight, fat accretion or glycemic control in MCD-diet fed mice, confirming the suitability of this model for avoiding confounding factors. Liraglutide treatment did not prevent lipid deposition in the liver of MCD-fed mice but limited the accumulation of C16 and C24-ceramide/sphingomyelin species. In addition, liraglutide treatment alleviated hepatic inflammation (in particular accumulation of M1 pro-inflammatory macrophages) and initiation of fibrosis. Liraglutide also influenced the composition of gut microbiota induced by the MCD-diet. This included recovery of a normal Bacteroides proportion and, among the Erysipelotrichaceae family, a shift between Allobaculum and Turicibacter genera. In conclusion, liraglutide prevents accumulation of C16 and C24-ceramides/sphingomyelins species, inflammation and initiation of fibrosis in MCD-diet-fed mice liver, suggesting beneficial hepatic actions independent of weight loss and global hepatic steatosis.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ceramide; Glucagon like peptide-1 receptor agonist; Methionine-choline deficient diet; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Type 2 diabetes; inflammation; microbiota

Year:  2020        PMID: 32711187     DOI: 10.1016/j.trsl.2020.07.008

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  20 in total

Review 1.  Contribution of specific ceramides to obesity-associated metabolic diseases.

Authors:  Philipp Hammerschmidt; Jens C Brüning
Journal:  Cell Mol Life Sci       Date:  2022-07-05       Impact factor: 9.207

Review 2.  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.

Authors:  Stergios A Polyzos; Dimitrios G Goulis; Olga Giouleme; Georgios S Germanidis; Antonis Goulas
Journal:  Curr Obes Rep       Date:  2022-05-02

Review 3.  GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.

Authors:  Yan Chen; Ying-Na Xu; Chen-Yu Ye; Wen-Bo Feng; Qing-Tong Zhou; De-Hua Yang; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2021-12-21       Impact factor: 7.169

4.  Changes in the gut bacterial communities in colon cancer surgery patients: an observational study.

Authors:  Mohamed Abbas; Nadia Gaïa; Nicolas C Buchs; Vaihere Delaune; Myriam Girard; Diego O Andrey; Jeremy Meyer; Jacques Schrenzel; Frédéric Ris; Stephan Harbarth; Vladimir Lazarevic
Journal:  Gut Pathog       Date:  2022-01-04       Impact factor: 4.181

5.  Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.

Authors:  Dakota R Kamm; Kelly D Pyles; Martin C Sharpe; Laura N Healy; Jerry R Colca; Kyle S McCommis
Journal:  J Biol Chem       Date:  2021-05-19       Impact factor: 5.157

6.  The Impact of Incretin-Based Medications on Lipid Metabolism.

Authors:  Habib Yaribeygi; Mina Maleki; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-12-29       Impact factor: 4.011

Review 7.  Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.

Authors:  Maria Mavromati; François R Jornayvaz
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

8.  Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.

Authors:  Maria Apostolopoulou; Ruth Gordillo; Sofiya Gancheva; Klaus Strassburger; Christian Herder; Irene Esposito; Matthias Schlensak; Philipp E Scherer; Michael Roden
Journal:  BMJ Open Diabetes Res Care       Date:  2020-11

9.  Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.

Authors:  Katharina Luise Hupa-Breier; Janine Dywicki; Björn Hartleben; Freya Wellhöner; Benjamin Heidrich; Richard Taubert; Young-Seon Elisabeth Mederacke; Maren Lieber; Konstantinos Iordanidis; Michael P Manns; Heiner Wedemeyer; Matthias Hardtke-Wolenski; Elmar Jaeckel
Journal:  Biomedicines       Date:  2021-03-30

Review 10.  Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.

Authors:  Baptist Gallwitz; Francesco Giorgino
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-29       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.